Production (Stage)
Coeptis Therapeutics Holdings, Inc.
COEP
$8.23
-$0.13-1.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.88% | 48.13% | 71.20% | 5.22% | 62.28% |
| Total Depreciation and Amortization | 17.74% | 2.12% | -0.82% | -0.04% | 3.60% |
| Total Amortization of Deferred Charges | -33.40% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.13% | -74.62% | -105.25% | 85.99% | -89.34% |
| Change in Net Operating Assets | -384.17% | -104.91% | -157.64% | -109.71% | -72.70% |
| Cash from Operations | -24.38% | 15.19% | 3.36% | 25.50% | -12.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | 100.00% | -- |
| Cash from Investing | -- | -- | -100.00% | 100.00% | -- |
| Total Debt Issued | -26.67% | -100.00% | 100.00% | -85.25% | -- |
| Total Debt Repaid | 23.90% | 81.86% | 100.00% | -- | -- |
| Issuance of Common Stock | -- | -94.29% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | 290.51% | -58.20% | 755.85% | -42.68% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 949.17% | -1,149.65% | 77.22% | -53.80% | 73.89% |